GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » Short Percentage of Float

OKUR (OnKure Therapeutics) Short Percentage of Float


View and export this data going back to 2024. Start your Free Trial

What is OnKure Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of OnKure Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, OnKure Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OnKure Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OnKure Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where OnKure Therapeutics's Short Percentage of Float falls into.


;
;

OnKure Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » Short Percentage of Float
Comparable Companies
NRXP PPCB OSTX LVTX DYAI KZR GRCE ESLA RNXT ALGS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
Website
https://www.onkuretherapeutics.com
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.